Pyrotinib (brand name Tyvyt)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Pyrotinib (brand name Tyvyt), covering 2024-11-29 to 2024-11-29. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial [Phase 2]